Joshua Levine Purchases 10,000 Shares of FocalTherics (NASDAQ:FOCL) Stock

FocalTherics (NASDAQ:FOCL) Director Joshua Levine acquired 10,000 shares of FocalTherics stock in a transaction dated Friday, August 14th. The shares were acquired at an average price of $4.75 per share, with a total value of $47,500.00. Following the completion of the transaction, the director owned 45,000 shares of the company’s stock, valued at approximately $213,750. This trade represents a 28.57% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

FocalTherics Price Performance

FOCL opened at $4.26 on Wednesday. FocalTherics has a 12 month low of $1.30 and a 12 month high of $6.40. The company has a current ratio of 1.34, a quick ratio of 0.99 and a debt-to-equity ratio of 1.79. The firm has a market cap of $159.66 million, a PE ratio of -4.14 and a beta of -0.04. The firm has a 50 day simple moving average of $5.38.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.19). FocalTherics had a negative net margin of 56.26% and a negative return on equity of 175.45%. The business had revenue of $13.20 million for the quarter. Equities analysts anticipate that FocalTherics will post -0.78 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on FOCL shares. Mizuho set a $15.00 target price on shares of FocalTherics and gave the company an “outperform” rating in a research report on Friday, July 17th. Weiss Ratings restated a “sell (d-)” rating on shares of FocalTherics in a research report on Monday. Piper Sandler restated a “neutral” rating and set a $4.00 price target on shares of FocalTherics in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday, June 2nd. Finally, Wall Street Zen cut shares of FocalTherics from a “hold” rating to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $7.75.

FocalTherics News Roundup

Here are the key news stories impacting FocalTherics this week:

• Positive Sentiment: FocalTherics insiders collectively purchased 116,000 shares for approximately $551,000 at $4.75 per share. Buyers included CEO Ryan Rhodes, CFO Kenneth Mobeck, General Counsel Sanket Shah, SVP Steven Annen, and several directors. The coordinated open-market purchases may signal that company leadership views recent weakness as an attractive entry point. FocalTherics insider buying report
• Positive Sentiment: Director Lance Willsey made the largest purchase at 50,000 shares, while CEO Ryan Rhodes bought 21,000 shares. Other executives and directors increased their holdings by roughly 2.8% to 196%, strengthening the insider-buying signal. FocalTherics director transaction filing
• Neutral Sentiment: Recent filings show several institutional investors initiated positions, and institutions collectively own 62.74% of FocalTherics. While this indicates continued professional-investor interest, the disclosed purchases vary considerably in size and do not establish a clear near-term catalyst.
• Neutral Sentiment: A recent article characterized FocalTherics as targeting market leadership following a “record-breaking quarter,” but the available report provides insufficient financial detail to independently assess the claim. FocalTherics market leadership article
• Negative Sentiment: The company’s latest quarterly loss was $0.39 per share, substantially worse than the expected $0.20 loss, on revenue of $13.20 million. FocalTherics also reported a negative net margin of 56.26% and analysts expect a full-year loss of approximately $0.78 per share, keeping profitability and financing risk in focus.
• Negative Sentiment: Analyst opinion is mixed: although some firms maintain Buy or Outperform ratings and a $7.75 consensus target, Piper Sandler rates the stock Neutral with a $4 target, while Wall Street Zen recently downgraded it to Sell. Shares also remain below their 50-day moving average of $5.38, reflecting continued technical weakness.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Leonteq Securities AG acquired a new position in FocalTherics during the fourth quarter worth about $313,000. Kovack Advisors Inc. acquired a new stake in FocalTherics in the 4th quarter valued at about $53,000. Rock Springs Capital Management LP lifted its holdings in FocalTherics by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after acquiring an additional 16,500 shares during the last quarter. Flax Pond Capital LLC bought a new position in shares of FocalTherics during the 4th quarter valued at about $2,623,000. Finally, SmartHarvest Portfolios LLC bought a new position in shares of FocalTherics during the 1st quarter valued at about $38,000. Institutional investors own 62.74% of the company’s stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.